Shenzhen Kangtai Biological Products Co Ltd (300601) - Net Assets

Latest as of March 2026: CN¥9.67 Billion CNY ≈ $1.41 Billion USD

Based on the latest financial reports, Shenzhen Kangtai Biological Products Co Ltd (300601) has net assets worth CN¥9.67 Billion CNY (≈ $1.41 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.99 Billion ≈ $2.05 Billion USD) and total liabilities (CN¥4.32 Billion ≈ $632.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300601 tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥9.67 Billion
% of Total Assets	69.1%
Annual Growth Rate	26.99%
5-Year Change	5.07%
10-Year Change	1210.42%
Growth Volatility	47.03

Shenzhen Kangtai Biological Products Co Ltd - Net Assets Trend (2012–2025)

This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's net assets have evolved over time, based on quarterly financial data. See 300601 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Shenzhen Kangtai Biological Products Co Ltd (2012–2025)

The table below shows the annual net assets of Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2025. For live valuation and market cap data, see Shenzhen Kangtai Biological Products Co (300601) total market value.

Year	Net Assets	Change
2025-12-31	CN¥9.63 Billion ≈ $1.41 Billion	-0.30%
2024-12-31	CN¥9.66 Billion ≈ $1.41 Billion	+1.25%
2023-12-31	CN¥9.54 Billion ≈ $1.40 Billion	+6.19%
2022-12-31	CN¥8.99 Billion ≈ $1.31 Billion	-1.98%
2021-12-31	CN¥9.17 Billion ≈ $1.34 Billion	+22.82%
2020-12-31	CN¥7.46 Billion ≈ $1.09 Billion	+170.98%
2019-12-31	CN¥2.75 Billion ≈ $403.03 Million	+49.92%
2018-12-31	CN¥1.84 Billion ≈ $268.83 Million	+71.53%
2017-12-31	CN¥1.07 Billion ≈ $156.72 Million	+45.72%
2016-12-31	CN¥735.00 Million ≈ $107.55 Million	+13.58%
2015-12-31	CN¥647.12 Million ≈ $94.69 Million	+10.84%
2014-12-31	CN¥583.81 Million ≈ $85.43 Million	+56.87%
2013-12-31	CN¥372.17 Million ≈ $54.46 Million	-13.69%
2012-12-31	CN¥431.21 Million ≈ $63.10 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shenzhen Kangtai Biological Products Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 4322.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥2.13 Billion	22.09%
Other Components	CN¥7.50 Billion	77.91%
Total Equity	CN¥9.63 Billion	100.00%

Shenzhen Kangtai Biological Products Co Ltd Competitors by Market Cap

The table below lists competitors of Shenzhen Kangtai Biological Products Co Ltd ranked by their market capitalization.

Company	Market Cap
FAIRFAX INDIA HLDGS F:F5X	$1.88 Billion
Dgb Financial KO:139130	$1.88 Billion
Mesoblast Ltd AU:MSB	$1.88 Billion
American Superconductor Corporation NASDAQ:AMSC	$1.88 Billion
Vietnam National Petroleum Group VN:PLX	$1.88 Billion
Surgery Partners Inc NASDAQ:SGRY	$1.88 Billion
Horace Mann Educators Corporation NYSE:HMN	$1.88 Billion
EMBOTELL. ANDINA ADR A/6 F:AKOA	$1.88 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shenzhen Kangtai Biological Products Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 9,661,123,922 to 9,631,743,291, a change of -29,380,631 (-0.3%).
Net income of 70,330,463 contributed positively to equity growth.
Dividend payments of 131,552,216 reduced retained earnings.
Other comprehensive income decreased equity by 3,277,783,693.
Other factors increased equity by 3,309,624,815.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥70.33 Million	+0.73%
Dividends Paid	CN¥131.55 Million	-1.37%
Other Comprehensive Income	CN¥-3.28 Billion	-34.03%
Other Changes	CN¥3.31 Billion	+34.36%
Total Change	CN¥-	-0.30%

Book Value vs Market Value Analysis

This analysis compares Shenzhen Kangtai Biological Products Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.34x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 24.47x to 1.34x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	CN¥0.47	CN¥11.52	x
2013-12-31	CN¥0.42	CN¥11.52	x
2014-12-31	CN¥0.70	CN¥11.52	x
2015-12-31	CN¥0.73	CN¥11.52	x
2016-12-31	CN¥0.82	CN¥11.52	x
2017-12-31	CN¥1.09	CN¥11.52	x
2018-12-31	CN¥1.84	CN¥11.52	x
2019-12-31	CN¥2.70	CN¥11.52	x
2020-12-31	CN¥6.94	CN¥11.52	x
2021-12-31	CN¥8.25	CN¥11.52	x
2022-12-31	CN¥8.12	CN¥11.52	x
2023-12-31	CN¥8.53	CN¥11.52	x
2024-12-31	CN¥8.62	CN¥11.52	x
2025-12-31	CN¥8.62	CN¥11.52	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shenzhen Kangtai Biological Products Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.73%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 2.63%
• Asset Turnover: 0.19x
• Equity Multiplier: 1.46x
Recent ROE (0.73%) is below the historical average (9.12%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	2.65%	9.35%	0.11x	2.64x	CN¥-31.67 Million
2013	0.41%	0.60%	0.23x	2.97x	CN¥-35.71 Million
2014	5.34%	10.27%	0.23x	2.30x	CN¥-27.22 Million
2015	9.71%	13.88%	0.34x	2.06x	CN¥-1.89 Million
2016	11.73%	15.62%	0.34x	2.18x	CN¥12.71 Million
2017	20.05%	18.49%	0.53x	2.06x	CN¥107.60 Million
2018	23.72%	21.60%	0.60x	1.82x	CN¥251.97 Million
2019	20.86%	29.56%	0.49x	1.44x	CN¥299.08 Million
2020	9.10%	30.04%	0.24x	1.28x	CN¥-67.16 Million
2021	13.78%	34.59%	0.26x	1.54x	CN¥346.70 Million
2022	-1.48%	-4.20%	0.23x	1.53x	CN¥-1.03 Billion
2023	9.03%	24.77%	0.23x	1.58x	CN¥-92.86 Million
2024	2.09%	7.60%	0.18x	1.51x	CN¥-764.46 Million
2025	0.73%	2.63%	0.19x	1.46x	CN¥-892.84 Million

Industry Comparison

This section compares Shenzhen Kangtai Biological Products Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,632,988,841
Average return on equity (ROE) among peers: 4.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shenzhen Kangtai Biological Products Co Ltd (300601)	CN¥9.67 Billion	2.65%	0.45x	$1.88 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.97 Billion	4.04%	0.54x	$565.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$654.09 Million	2.17%	0.78x	$359.03 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$0.00	0.00%	0.00x	$4.30 Billion
Livzon Pharmaceutical Group Inc (000513)	$973.90 Million	0.17%	0.60x	$2.52 Billion
Wedge Industrial Co Ltd (000534)	$1.29 Billion	11.69%	1.47x	$2.41 Billion
Yunnan Baiyao Group Co Ltd (000538)	$3.19 Billion	14.61%	0.55x	$12.64 Billion
Hainan Haiyao Co Ltd (000566)	$353.98 Million	-9.58%	0.80x	$715.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$307.22 Million	6.68%	0.79x	$319.94 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$2.55 Billion	4.67%	3.16x	$916.75 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$25.04 Billion	7.11%	0.16x	$3.00 Billion

About Shenzhen Kangtai Biological Products Co Ltd

SHE:300601 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.88 Billion

CN¥12.87 Billion CNY

Market Cap Rank

#6506 Global

#1402 in China

Share Price

CN¥11.52

Change (1 day)

-0.17%

52-Week Range

CN¥11.49 - CN¥20.49

All Time High

CN¥148.10